DXVX outside director Jung Seok-ho reported acquiring 1,333 shares through new appointment (333 shares) and market purchase (1,000 shares) in April 2026.
DXVX seeks tech transfer for cancer vaccine, oral obesity drug in Europe
DXVX to participate in BIO-EUROPE SPRING 2026, seeking technology transfer for cancer vaccine OVM-200 and oral obesity treatment. Company to meet with 30 global pharmaceutical and biotech firms.
DXVX seeks licensing opportunities at JP Morgan Healthcare Conference
DXVX to participate in JP Morgan Healthcare Conference and Biotech Showcase 2026, seeking global licensing opportunities and strategic partnerships for its innovative healthcare technologies.
JPMorgan: Crypto Market Structure Act likely to pass mid-year
JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.
Get full access to view complete information
1 - 25 of 34
Get full access to view complete information
Frequently Asked Questions Regarding Dx & Vx
Company Overview
2007
Founded
Biotechnology Research
Industry
South Korea
Location
10,158,081
Ranking
32 employees
Size
Similar Companies
Get full access to view complete information
Frequently Asked Questions Regarding Dx & Vx
Start your journey today
Start with the platform — or start with a conversation
Use Pubrio on your own, or let our team help you with research, lead generation, or data integration.